Picton Mahoney Asset Management Makes New $1.06 Million Investment in Veeva Systems Inc. $VEEV

Picton Mahoney Asset Management bought a new stake in shares of Veeva Systems Inc. (NYSE:VEEV) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,564 shares of the technology company’s stock, valued at approximately $1,062,000.

A number of other hedge funds have also modified their holdings of VEEV. Vanguard Group Inc. boosted its position in Veeva Systems by 3.1% during the third quarter. Vanguard Group Inc. now owns 15,429,231 shares of the technology company’s stock valued at $4,596,522,000 after purchasing an additional 457,806 shares during the last quarter. Alliancebernstein L.P. increased its position in Veeva Systems by 3.7% in the 2nd quarter. Alliancebernstein L.P. now owns 5,705,648 shares of the technology company’s stock worth $1,643,113,000 after purchasing an additional 205,997 shares during the last quarter. Principal Financial Group Inc. increased its position in Veeva Systems by 11.2% in the 3rd quarter. Principal Financial Group Inc. now owns 3,846,877 shares of the technology company’s stock worth $1,146,040,000 after purchasing an additional 388,864 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Veeva Systems by 4.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,476,258 shares of the technology company’s stock worth $1,035,622,000 after purchasing an additional 159,984 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Veeva Systems by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock valued at $888,108,000 after buying an additional 114,003 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total value of $231,430.00. Following the sale, the insider owned 23,204 shares of the company’s stock, valued at $5,370,101.72. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 10.30% of the stock is currently owned by insiders.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Q4 beat and raised guidance — Veeva reported Q4 revenue of ~$836M (+16% YoY) and non‑GAAP EPS of $2.06, topping estimates; management issued FY27 and Q1 EPS/revenue guidance above consensus, which is the main catalyst for the stock move. Veeva Announces Fourth Quarter and Fiscal Year 2026 Results
• Positive Sentiment: AI initiatives and product momentum — Analysts and deep‑dive coverage point to expanding AI capabilities and core systems modernization (agentic/AI features and CRM expansion) driving subscription demand and revenue durability. Investors view this as evidence Veeva can outperform broader software AI fears. VEEV Q4 Deep Dive: AI Initiatives and Core Systems Modernization Drive Outperformance
• Positive Sentiment: Support from some analysts — Several firms reaffirmed buys or raised targets after the print (examples include Stifel and Truist), signaling continued institutional confidence despite a mixed overall reactions. Veeva Systems Analyst Says AI Push Keeps Stock Attractive
• Neutral Sentiment: Mixed analyst price‑target moves — The earnings beat prompted a flurry of target changes (some higher, some lower); the net effect is varied positioning rather than a clear consensus upgrade. Watch flows as firms update models. These Analysts Cut Their Forecasts On Veeva Systems Following Q4 Results
• Neutral Sentiment: ETF / positioning chatter — Higher premarket/ETF positioning mentions (e.g., Russell 1000 activity) could amplify intraday moves but don’t change fundamentals. Veeva Systems Sparks Elevated Positioning Chatter In Russell 1000 ETF
• Negative Sentiment: Analyst downgrades and target cuts remain — A number of firms trimmed targets (Piper, Needham, RBC, Canaccord among others) and some flagged decelerating growth/margin pressure; these cuts could cap near‑term upside and increase volatility. These Analysts Cut Their Forecasts On Veeva Systems Following Q4 Results
• Negative Sentiment: Competitive/CRM risks and margin scrutiny — Coverage highlights CRM competition and questions about pace of AI monetization; if CRM wins slow or margins compress, guidance may prove optimistic. Veeva Systems Under Pressure as Earnings Loom Amid CRM Competition

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on VEEV shares. KeyCorp reaffirmed a “sector weight” rating on shares of Veeva Systems in a research report on Friday, December 12th. UBS Group increased their price target on shares of Veeva Systems from $200.00 to $220.00 and gave the stock a “neutral” rating in a research note on Thursday. Truist Financial reaffirmed a “buy” rating and issued a $262.00 price objective (down from $275.00) on shares of Veeva Systems in a research note on Thursday. Weiss Ratings downgraded shares of Veeva Systems from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 12th. Finally, Piper Sandler cut their target price on Veeva Systems from $355.00 to $285.00 and set an “overweight” rating on the stock in a report on Thursday. Seventeen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Veeva Systems has a consensus rating of “Moderate Buy” and an average target price of $284.91.

Veeva Systems Trading Up 4.1%

NYSE:VEEV opened at $196.29 on Friday. The firm has a market capitalization of $32.27 billion, a PE ratio of 36.28, a PEG ratio of 1.30 and a beta of 1.09. Veeva Systems Inc. has a 1 year low of $168.13 and a 1 year high of $310.50. The firm’s fifty day simple moving average is $204.04 and its 200 day simple moving average is $248.03.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Wednesday, March 4th. The technology company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The company had revenue of $835.95 million during the quarter, compared to analysts’ expectations of $810.95 million. Veeva Systems had a net margin of 28.44% and a return on equity of 14.11%. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.74 earnings per share. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. As a group, analysts anticipate that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Veeva Systems announced that its Board of Directors has initiated a stock repurchase program on Monday, January 5th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the technology company to buy up to 5.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.